Validation of diagnosis criteria for acquired sensory neuronopathy. a francophone multicenter study

Détails

ID Serval
serval:BIB_63124ED8578B
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Validation of diagnosis criteria for acquired sensory neuronopathy. a francophone multicenter study
Titre de la conférence
Meeting of the Peripheral Nerve Society
Auteur⸱e⸱s
Antoine J.-.C., Abba K., Franques J., Pouget J., Delmont E., Kuntzer T., Petiot P., Gervais-Bernard H., Echaniz-Laguna A., Creange A., Mathis S., Camdessanche J.-.P.
Adresse
Potomac, Maryland, June 25-29, 2011
ISBN
1085-9489
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
16
Série
Journal of the Peripheral Nervous System
Pages
S3-S4
Langue
anglais
Notes
Publication type : Meeting Abstract
Résumé
Recently published criteria using clinical (ataxia or asymmetrical distribution at onset or full development, and sensory loss not restricted to the lower limbs) and electrophysiological items (less than two abnormal lower limb motor nerves and at least an abolished SAP or three SAP below 30% of lower limit of normal in the upper limbs) were sensitive and specific for the diagnosis of sensory neuronopathy (SNN) (Camdessanche et al., Brain, 2009). However, these criteria need to be validated on a large multicenter population. For this, a database collecting cases from fifteen Reference Centers for Neuromuscular diseases in France and Switzerland is currently developed. So far, data from 120 patients with clinically pure sensory neuropathy have been collected. Cases were classified independently from the evaluated criteria as SNN (53), non-SNN (46) or suspected SNN (21) according to the expert's diagnosis. Using the criteria, SNN was possible in 83% (44/53), 23.9% (11/46) and 71.4% (15/21) of cases, respectively. In the non-SSN group, half of the patients with a diagnosis of possible SSN had an ataxic form of inflammatory demyelinating neuropathy. In the SNN group, half of those not retained as possible SNN had CANOMAD, paraneoplasia, or B12 deficiency. In a second step, after application of the items necessary to reach the level of probable SNN (no biological or electrophysiological abnormalities excluding SNN; presence of onconeural antibody, cisplatin treatment, Sj ¨ ogren's syndrome or spinal cord MRI high signal in the posterior column), a final diagnosis of possible or probable SNN was obtained in, respectively, 90.6% (48/53), 8.8% (4/45), and 71.4% (15/21) of patients in the three groups. Among the 5 patients with a final non-SNN but initial SNN diagnosis, 3 had motor conduction abnormalities (one with CANOMAD) and among the 4 patients with a final SNN but initial non-SSN diagnosis, one had anti-Hu antibody and one was discussed as a possible ataxic CIDP. These preliminary results confirm the sensitivity and specificity of the proposed criteria for the diagnosis of SNN.
Web of science
Création de la notice
01/09/2011 13:22
Dernière modification de la notice
20/08/2019 15:19
Données d'usage